Perioperative Lung Protection Provided by High-Dose Ambroxol in Patients with Lung Cancer.
The purpose is to observe the clinical effect of large doses of ambroxol hydrochloride in lung protection during the perioperative period of lung cancer operation. Fifty-six lung cancer patients who have undergone open-thoracic pulmonary lobectomy were divided randomly into two groups, and were given normal and large doses of ambroxol hydrochloride, respectively, during their perioperative period. Statistics based on post-operation clinical observations were analyzed in terms of ease of expectoration and expectoration properties, duration of antibiotics dependence, occurrence of lung complications, and adverse reactions related to ambroxol hydrochloride. On the third and the seventh day, the experimental group showed signs of improvement in terms of ease of expectoration and expectoration properties, compared with the controlled group. In terms of occurrence of post-operation lung complications and duration of antibiotics dependence, the experimental group also performed better. Using large doses of ambroxol hydrochloride would result in better clinical effects than using normal doses in preventing post-operation complications, and its clinical value in lung protection during lung cancer perioperative period calls for further research and promotion.
Department of Thoracic Surgery, Xuzhou Central Hospital, Jiefang Road No. 199, Xuzhou City, Jiangsu Province, China.
Xin
X
Wang
Department of Thoracic Surgery, Xuzhou Central Hospital, Jiefang Road No. 199, Xuzhou City, Jiangsu Province, China. contribution066@163.com.
Lei
L
Wang
Department of Thoracic Surgery, Xuzhou Central Hospital, Jiefang Road No. 199, Xuzhou City, Jiangsu Province, China.
Huayong
H
Wang
Department of Thoracic Surgery, Xuzhou Central Hospital, Jiefang Road No. 199, Xuzhou City, Jiangsu Province, China.
Hao
H
Zhang
D000551:Ambroxol / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000517:prevention & control; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D059035:Perioperative Period; D011183:Postoperative Complications / Q000517:prevention & control; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D005100:Expectorants; D000551:Ambroxol
Ambroxol hydrochloride; Antibiotics; Complications; Lung cancer